Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations

Therapeutic Drug Monitoring

Volumn 29, Issue 4, 2007, Pages 455-459

  Lee, Sang Seop ^a   Lee, Su Jun ^a   Gwak, Jungsug ^a   Jung, Hyun Ju ^a   Thi Le, Houng ^a   Song, Im Sook ^a   Kim, Eun Young ^a   Shin, Jae Gook ^a  

^a Inje University College of Medicine   (South Korea)

Author keywords

Allele frequency; CYP2C19; Genotype; Korean; Vietnamese

Indexed keywords

CYTOCHROME P450 2C19;

ALLELE; ARTICLE; ASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNIC DIFFERENCE; ETHNIC GROUP; FAR EAST; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KOREA; MALE; METABOLISM; PRIORITY JOURNAL; VIET NAM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; GENOTYPE; HUMANS; KOREA; MALE; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; VIETNAM;

EID: 34547655752     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31811f383c     Document Type: Article

References (19)

1. de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994;269:15419-15422.
2. de Morais SM, Goldstein JA, Xie HG, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther. 1995;58:404-411.
3. Wang S-L, Huang J-D, Lai M-D, et al. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5:37-42.
4. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP 2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6:341-349.
5. Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit. 1996;18:393-396.
6. de Morais SM, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin hydroxylase in Japanese. Mol Pharmacol. 1994;48:594-598.
7. Xiao ZS, Goldstein JA, Xie HG, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther. 1997;281:604-609.
8. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60:661-666.
9. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59-64.
10. Tassaneeyakul W, Tawalee A, Tassaneeyakul W, et al. Analysis of the CYP2C19 polymorphism in a north-eastern Thai population. Pharmacogenetics. 2002;12:221-225.
11. Roh HK, Dahl ML, Tybring G, et al. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics. 1996;6:547-551.
12. Yamada S, Onda M, Kato S, et al. Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol. 2001;36:669-672.
13. Brosen K, Skejelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol. 1993;36:105-108.
14. Lee SS, Jeong HE, Liu KH, et al. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics. 2005;15:279-290.
15. Yoon YR, Lee JH, Kim MK, et al. Frequency distribution of cytochrome P450 2C19 genotypes in a Korean population. Kor J Clin Pharmacol Ther. 2002;68:1019-1029.
16. Ward SA, Helsby NA, Skjelbo E, et al. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism: a panel study. Br J Clin Pharmacol. 1991;31:689-692.
17. Bertilsson L, Dahl ML, Ingelman-Sundberg M, et al. Interindividual and interethnic differences in polymorphic drug oxidation: implications for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN, eds. Advances in Drug Metabolism in Man. DGXII-E-4eur1549 EN, EC. Luxembourg: Office For Official Publications of the European Communities; 1995:85-136.
18. Kaneko A, Berqvist Y, Taleo G, et al. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics. 1999;9:317-326.
19. Eriksson S, Berg LM, Wadelius M, et al. Cytochrome P450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev Technol. 2002;1:49-59.